# Keros Therapeutics share price today (Keros Therapeutics, Inc., KROS)

> Keros Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. KROS · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/kros

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $10.83 (−33.1% in a year)
- Revenue (Mar 2026): ₹0.0 B
- Profit (Mar 2026), incl. one-off: ₹0.0 B (one-off item, see below)
- Operating margin: −7,051.0% (−7,123.0 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Keros Therapeutics share price today? Keros Therapeutics, Inc.'s share price was $10.83 at the close on 4 November 2026. That is 9.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between $10 and $22, and at that close it sat 7% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 1 year the share price moved −25% while the S&P 500 moved +18%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Keros Therapeutics pay? Keros Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Keros Therapeutics on? Keros Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Keros Therapeutics profitable? Keros Therapeutics, Inc. posted a net loss of ₹0.02 B in the Mar 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. Full-year FY25 profit was ₹0.1 B. That loss is 6,459.9% of the quarter's revenue. The same quarter a year earlier earned ₹0.1 B. 11 of the last 12 reported quarters were loss-making. Mar 2026 profit was ₹0.0 B, −116.0% on a year earlier. Read this profit with care: at ₹0.0 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −7,051.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Keros Therapeutics make, and is it growing? Keros Therapeutics, Inc. reported ₹0.0 B of revenue in the Mar 2026 quarter, −99.8% on the same quarter a year earlier. Over 4 years it has grown 86.7% a year on average. The last full year, FY25, came in at ₹0.2 B. The last four reported quarters add to ₹0.0 B. FY25 revenue was ₹0.2 B, +6,775.0% on the year before. Recent pace: the last four quarters grew +1,129.6% on average, against 86.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −84.5%, against +28.1% a year over the last 8 quarters (rolling over). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Keros Therapeutics keep? Keros Therapeutics, Inc.'s operating margin was −7,051.0% in the Mar 2026 quarter, 7,123.0 percentage points lower than the same quarter a year ago. Across 4 years it has been between −1,12,543.7% and 28.9%. The latest quarter is within that range. Why the margin moved: operating margin changed −7,123.0 percentage points on the year while gross margin changed −4,363.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Keros Therapeutics' profit turning into cash? Keros Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in ₹0.1 B of operating cash against ₹0.1 B of profit. After ₹0.0 B of spending on assets, ₹0.1 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Keros Therapeutics' cash go? Keros Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Keros Therapeutics' P/E ratio, and how does it compare with its own history? Keros Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Keros Therapeutics business getting better or worse? Keros Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 5 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Keros Therapeutics earn on its capital? Keros Therapeutics, Inc. earned a ROE of 29% in FY25. That is up from a low of −46% in FY23. Its return on capital used (ROIC) is left out: on sales this small it reads −1,252%, a number that says nothing useful about the business. It comes from a 35.7% net margin and 0.72× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 35.7% net margin × 0.72× asset turnover × 1.12× leverage (assets divided by equity) ≈ 28.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. ## Does Keros Therapeutics have too much debt? Keros Therapeutics, Inc. has total debt of ₹0.0 B against shareholder equity of ₹0.3 B as of Jun 2026, so its debt is 0.06× its equity, which is very little. Year by year, that ratio went from 0.00 in FY21 to 0.06 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Keros Therapeutics shareholding pattern? 6.4% of Keros Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Keros Therapeutics from balance-sheet trouble? For Keros Therapeutics, Inc., the Z-score is 8.22. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 8.22 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Keros Therapeutics rank in its industry? There is no score against its industry: Keros Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Keros Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Keros Therapeutics in size? Keros Therapeutics is the 192nd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: InflaRx N.V., Protalix BioTherapeutics, Inc. and Sol-Gel Technologies. Just below it: Cartesian Therapeutics, Inc., Artiva Biotherapeutics, Inc. and Upstream Bio, Inc. ### Biotechnology companies close in size

1. [InflaRx N.V.](https://www.sectoralpha.in/us/stocks/ifrx) $218 million
2. [Protalix BioTherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/plx) $217 million
3. [Sol-Gel Technologies Ltd.](https://www.sectoralpha.in/us/stocks/slgl) $216 million
4. Keros Therapeutics, Inc. $215 million
5. [Cartesian Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/rnac) $206 million
6. [Artiva Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/artv) $206 million
7. [Upstream Bio, Inc.](https://www.sectoralpha.in/us/stocks/upb) $203 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Evommune, Inc.](https://www.sectoralpha.in/us/stocks/evmn) $216 million · Biotechnology
2. [Modiv Industrial, Inc.](https://www.sectoralpha.in/us/stocks/mdv) $215 million · REIT - Industrial
3. Keros Therapeutics, Inc. $215 million
4. [TriSalus Life Sciences, Inc.](https://www.sectoralpha.in/us/stocks/tlsi) $214 million · Medical Devices
5. [Consumer Portfolio Services, Inc.](https://www.sectoralpha.in/us/stocks/cpss) $213 million · Credit Services

## What else do people ask about Keros Therapeutics? ### What were Keros Therapeutics's latest quarterly results? Keros Therapeutics, Inc. reported revenue of ₹0.0 B and a net loss of ₹0.0 B for the Mar 2026 quarter. Revenue fell 99.8% and profit fell 116.0% compared with a year earlier. The operating margin was −7,051.0%, 7,123.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is Keros Therapeutics's market cap? Keros Therapeutics, Inc.'s market capitalisation is $215 M at a stock price of $10.83. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Keros Therapeutics performing? Keros Therapeutics, Inc.'s latest readings are below. In its latest quarter, revenue fell 99.8% and profit fell 116.0% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Keros Therapeutics's stock price go up? This page does not forecast Keros Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $10.83. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Keros Therapeutics in its business cycle? Keros Therapeutics, Inc.'s FY25 operating margin was 28.9%, against a 4-year range of −1,12,543.7% to 28.9%: the middle of its own range, neither a peak nor a low. The latest quarter was −7,051.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Keros Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Keros Therapeutics a stock worth studying right now? What the numbers show: Keros Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.